science

Juno Therapeutics

Juno Therapeutics is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Juno Therapeutics rather than just read about it. In short: Juno Therapeutics, Inc. was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs.

Key takeaways

Juno Therapeutics belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Juno Therapeutics to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Juno Therapeutics from memory before moving on to harder problems.

Reference excerpt

Juno Therapeutics, Inc. was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion. In November 2019, Bristol-Myers Squibb (BMS) announced that it has completed its acquisition of Celgene.

History In December 2014 the company signed an agreement with Opus Bio, Inc for a chimeric antigen receptor (CAR-T) cell product candidate targeting CD22. In April 2015 the company entered into a collaboration with MedImmune (a subsidiary of AstraZeneca) investigating combination treatments for cancer. The trials will assess combinations of MEDI4736 and one of Juno's CD19 directed chimeric antigen receptor T cell candidates. In May 2015, the company announced its intention to acquire Stage Cell Therapeutics for up to $223 million. Later in the same month the company launched a collaboration, with Editas Medicine, to create CAR-T and high-affinity T cell receptor therapies to treat cancer, with the potential to generate up to $737 million-plus for Editas. In June, the company acquired X-Body for more than $44 million. In June, the company announced a 10-year partnership with Celgene valued at $1 billion. As part of the deal Celgene will pay Juno $150 million and acquire 9.1 million new Juno shares (valued at $93, existing Juno shares rose 26% to $58.38). Celgene will gain the right to sell Juno's therapies around the world. This partnership surpasses the previous highest record when Pfizer agreed to a deal with Merck KGaA in 2014. In January 2016 Juno announced it had acquired AbVitro, allowing it to use next-generation single cell sequencing platforms to complement its ability to create T cells engineered to target a broad array of cancer targets. Later in July of the same year, the company announced it would acquire RedoxTherapies for $10 million. This acquisition provides Juno with an exclusive license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers. In August the company announced it would license rights from Memorial Sloan Kettering Cancer Center and Eureka Therapeutics for a novel, fully human binding domain targeting B-cell maturation antigen. In January 2018, Celgene announced it would acquire Juno for $9 billion.

Drug approval Lisocabtagene maraleucel (liso-cel), the company's autologous anti-CD19 chimeric antigen receptor (CAR) T-cell immunotherapy with a defined composition of purified CD8+ and CD4+ CAR T cells for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies. On February 5, 2021, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment.

Worked examples

Example 1 — a first encounter with Juno Therapeutics

Start with the simplest possible case. Write down what Juno Therapeutics claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Juno Therapeutics before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Juno Therapeutics ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Juno Therapeutics

In research: Juno Therapeutics appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Juno Therapeutics in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Juno Therapeutics is common in secondary-school and first-year university syllabi. It links to neighbouring topics 2013 establishments in Washington (state), 2018 mergers and acquisitions, Biotechnology companies established in 2013, so understanding it makes those chapters shorter.
In everyday life: Look for Juno Therapeutics outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Juno Therapeutics” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Juno Therapeutics in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Juno Therapeutics means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Juno Therapeutics out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Juno Therapeutics in simple terms?

Why does Juno Therapeutics matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Juno Therapeutics?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Juno Therapeutics.